← Patent-cliff monitor Loss of exclusivity January 2043 latest FDA-listed patent expiry
Drug detail Brand name IGALMI Active ingredient DEXMEDETOMIDINE HYDROCHLORIDE Strength EQ 0.18MG BASE Dosage form FILM Route BUCCAL, SUBLINGUAL Modality Small molecule FDA approval April 2022 Marketing status RX
Listed patents Patent Expires Type 12138247 January 2043 use U-4029 12090140 January 2043 use U-3986 11806334 January 2043 use U-3725 11998528 January 2043 use U-3935 12364683 January 2043 use U-4029 11998529 July 2040 use U-3935 12109196 July 2040 use U-3935 11890272 July 2040 use U-3756 11517524 June 2039 product 11497711 June 2039 product 10792246 June 2039 product 11478422 June 2039 product 11839604 December 2037 use U-3756 11786508 December 2037 use U-3698
Regulatory exclusivity Code Expires M-82 November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.